PCSK9 is a protein with proven deleterious effects on lipid metabolism. PCSK9 facilitates the degradation of the LDL receptors on the surface of hepatocytes. As a result, LDL concentrations in the serum increase. Statin therapy stimulates a positive feedback circle which causes PCSK9 levels to increase, attenuating statin’s efficiency. PCSK9 inhibitors have proven themselves in several clinical trials as safe drugs that cause significant improvements in lipid profiles. The purpose of this review is to fully delineate the link between PCSK9 and atherosclerosis, as well as the future of PCSK9 inhibition.